In 2001, a self-administered questionnaire was sent to 1000 corn, Zea mays L., farmers in each of five states (Illinois, Indiana, Iowa, Minnesota, and Nebraska) to evaluate their perceptions of transgenic corn designed to control the European corn borer, Ostrinia nubilalis (Hübner), and corn rootworms, Diabrotica spp. Respondents returned 1,313 surveys (26.2%). Farmers with small acreages planted a greater portion of their corn (54.5%) with transgenic corn for control of European corn borer than farmers with large farms (39.2%). The majority (75.2%) of farmers use crop rotation to control the corn rootworm. Nine insecticides comprised 92.2% of the commercial soil insecticides used for control of corn rootworm larvae. More than one-third of the farmers in Illinois (33.5%) and Indiana (39.4%) treated first-year corn for corn rootworm, primarily due to western corn rootworm egg laying in soybean, Glycine max (L.). When asked whether they would plant transgenic corn protected against the corn rootworm, 35.0% of farmers responded they would, whereas 40.5% said they were unsure. The two greatest farmer concerns about transgenic corn were the ability to sell harvested grain (59.3%) and additional technology fees (54.8%). Respondents indicated that less farmer exposure to insecticide (69.9%) and less insecticide in the environment (68.5%) were the primary benefits of transgenic corn. Farmers who had no concerns about transgenic corn for rootworm control were more likely to purchase the product (46.8%). The most common refuge-planting options farmers favored were adjacent fields (30.9%) and split fields (29.9%). Farmers (21.1%) observed a yield increase (23.7 bu/ha [9.6 bu/acre]) when using transgenic corn for European corn borer control compared with nontransgenic corn. These data can help in understanding farmers’ knowledge and concerns regarding transgenic corn. This information may be of value to guide researchers, extension specialists, and policy makers in designing insect resistance management and integrated pest management programs.
You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither BioOne nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the BioOne website.
Vol. 98 • No. 2